8/3/2023 0 Comments Owens and minorThis release contains certain ''forward-looking'' statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. Conference call participants are required to register in advance to obtain call-in information prior to the start of the call. The live webcast will be available on Owens & Minor’s Investor Relations website in the Events & Presentations section. ET today, November 2, 2022, to discuss the results. Owens & Minor executives will host a conference call at 8:30 am. Investor Conference Call for Third Quarter 2022 Financial Results Revenue for 2022 to be in a range of $9.8 billion to $10.0 billion, reflecting:Ĭontribution in excess of $0.9 billion from ApriaĪdjusted EBITDA for 2022 to be in a range of $527 million to $537 millionĪdjusted EPS for 2022 to be in a range of $2.50 to $2.60 The Company’s outlook for 2022 is summarized below: "Overall, our core business fundamentals remain strong, we have the right strategy, and our portfolio is well positioned to capitalize on opportunities as our execution and market conditions improve," Pesicka concluded. This exceptional performance was supported by deep adoption of the Owens & Minor Business System and led to nearly 100 basis point margin expansion sequentially and year-over-year revenue growth of 11.4% on a pro forma basis for the Apria acquisition." Pesicka added, "I am very pleased with the performance and operational execution throughout all aspects of the Patient Direct Segment, including the capture of increased CPAP opportunities, and overachievement of acquisition synergies. "To better address these challenges and capitalize on opportunities, we are accelerating execution of key initiatives to improve the segment’s performance." Pesicka, President & Chief Executive Officer of Owens & Minor. "In the third quarter we saw greater than expected macro-economic and industry-related forces that continue to challenge our Products & Healthcare Services segment and as the quarter progressed, we saw more of our acute care customers delay reorders utilizing their stockpiled items," said Edward A. (NYSE-OMI) today reported financial results for the third quarter ended September 30, 2022, as summarized in the table below. RICHMOND, Va., November 02, 2022-( BUSINESS WIRE)-Owens & Minor, Inc. Generated $69 million of cash from operations in the quarter Patient Direct Revenue Growth of 142%, or 11.4% on a Pro Forma Basis for the Apria Acquisition The firm decreased its portfolio allocation in OMI by 25.35% over the last quarter.Adjusted EBITDA of $127 million, margin up 140 basis points In it's prior filing, the firm reported owning 5,579K shares, representing an increase of 1.24%. IJR - iShares Core S&P Small-Cap ETF holds 5,649K shares representing 7.41% ownership of the company. Wellington Management Group Llp holds 7,468K shares representing 9.80% ownership of the company. The put/call ratio of OMI is 0.98, indicating a bullish outlook. Total shares owned by institutions increased in the last three months by 0.37% to 87,943K shares. Average portfolio weight of all funds dedicated to OMI is 0.12%, a decrease of 14.82%. This is a decrease of 20 owner(s) or 3.47% in the last quarter. There are 556 funds or institutions reporting positions in Owens & Minor. The projected annual non-GAAP EPS is 2.43. The projected annual revenue for Owens & Minor is 10,237MM, an increase of 1.64%. See our leaderboard of companies with the largest price target upside.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |